search
Back to results

Safety and Efficacy of CJ-50300 in Healthy Volunteers

Primary Purpose

Smallpox

Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
smallpox vaccine CJ-50300
Sponsored by
Seoul National University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Smallpox focused on measuring Smallpox vaccine efficacy

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy Korean male and female subjects between 20 and 60 years of age at the time of screening visit
  2. Willing to participate and have signed the informed consent form
  3. In good general health, without clinically skin diseases history, physical examination or laboratory test results
  4. Hematocrit > 33% for women; > 38% for men
  5. White cell count 3,300-12,000/mm3
  6. Total lymphocyte count > 800 cells/mm3
  7. Subjects who have never been vaccinated with smallpox vaccines

Exclusion Criteria:

  1. Diseases or conditions that cause immunodeficiency (For examples; HIV AIDS, leukemia, lymphoma, generalized malignancy, agammaglobulinemia, history of transplantation, therapy with alkylating agents, antimetabolites, radiation, or oral or parenteral corticosteroids).
  2. In close physical contact (household or at work) with an individual who has the diseases or conditions that cause immunodeficiency
  3. History or present of eczema or atopic dermatitis
  4. Allergy or sensitivity to any known components of vaccine or other medicines
  5. In close physical contact (household or at work) with an individual who has acute or chronic skin conditions such as dermatitis, exfoliative dermatitis
  6. Subjects requiring steroid therapy
  7. Subjects who are taking immunosuppressive therapy
  8. Subjects who are planning for blood donations
  9. Autoimmune disease such as lupus erythematosus
  10. Subjects who work in medical institution
  11. Household contacts with women who are pregnant or breast-feeding
  12. Female subjects who are pregnant or breast-feeding and have positive result by serum pregnancy test or urine pregnancy test, or do not using approved contraceptives such as sterilization, contraceptive ring injectable, combined oral contraceptive pills and barrier contraceptive, combined hormone-based therapy, contraceptive cream, contraceptive jelly, diaphragm or condoms
  13. Subjects household member < 1 year old or work with children < 1 year old
  14. Subjects with a known history of Cardiac disease or have three or more of the following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis, cerebral arteriosclerosis
  15. Receipt of immunoglobulin and steroid within 14 days of vaccination
  16. Receipt of investigational research agents within 120 days of vaccination
  17. HBsAg seropositive
  18. HCV antibody seropositive
  19. HIV seropositive
  20. Subjects having fever (oral temperature > 38℃) or severe nutrition disorder
  21. Blood donation within 12 weeks in advance screening visit
  22. Subject who are not suitable to participate in study according to investigator's judgement

Sites / Locations

  • Seoul National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Conventional dose group

Low dose group

Arm Description

Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination

Diluted CJ-50300 2.5 x 10000pfu/dose vaccination

Outcomes

Primary Outcome Measures

Cutaneous Take Reaction
The "take reaction"was defined as a vesicular or pustular lesion or an area of definite palpable induration or congestion surrounding a central lesion (a crust or ulcer) occurring at the vaccination site at any of post-vaccination days (PVDs) 6-8. The vaccination site was photographed, and measures were taken.
Adverse Reactions

Secondary Outcome Measures

Antibody Response
Cell-mediate Immunity

Full Information

First Posted
January 31, 2008
Last Updated
July 7, 2013
Sponsor
Seoul National University Hospital
Collaborators
HK inno.N Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00607243
Brief Title
Safety and Efficacy of CJ-50300 in Healthy Volunteers
Official Title
Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
Collaborators
HK inno.N Corporation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The currently available stock of smallpox vaccine would be insufficient in the face of an incident of smallpox attack. Thus, new manufacturing methods for smallpox vaccine are urgently needed because previous manufacturing methods using calf lymph are no longer acceptable in the view of current standards. Recently, CJ corporation in Republic of Korea has developed cell-culture derived smallpox vaccine (CJ-50300) which was manufactured by infecting MRC-5 cells. The aim of this clinical trial were to assess safety, reactogenicity, and immunogenicity of CJ-50300.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smallpox
Keywords
Smallpox vaccine efficacy

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
123 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Conventional dose group
Arm Type
Experimental
Arm Description
Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
Arm Title
Low dose group
Arm Type
Experimental
Arm Description
Diluted CJ-50300 2.5 x 10000pfu/dose vaccination
Intervention Type
Biological
Intervention Name(s)
smallpox vaccine CJ-50300
Other Intervention Name(s)
CJ-53300
Intervention Description
Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
Primary Outcome Measure Information:
Title
Cutaneous Take Reaction
Description
The "take reaction"was defined as a vesicular or pustular lesion or an area of definite palpable induration or congestion surrounding a central lesion (a crust or ulcer) occurring at the vaccination site at any of post-vaccination days (PVDs) 6-8. The vaccination site was photographed, and measures were taken.
Time Frame
7-9 day
Title
Adverse Reactions
Time Frame
0-28 days
Secondary Outcome Measure Information:
Title
Antibody Response
Time Frame
14 or 28 days
Title
Cell-mediate Immunity
Time Frame
14 or 28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy Korean male and female subjects between 20 and 60 years of age at the time of screening visit Willing to participate and have signed the informed consent form In good general health, without clinically skin diseases history, physical examination or laboratory test results Hematocrit > 33% for women; > 38% for men White cell count 3,300-12,000/mm3 Total lymphocyte count > 800 cells/mm3 Subjects who have never been vaccinated with smallpox vaccines Exclusion Criteria: Diseases or conditions that cause immunodeficiency (For examples; HIV AIDS, leukemia, lymphoma, generalized malignancy, agammaglobulinemia, history of transplantation, therapy with alkylating agents, antimetabolites, radiation, or oral or parenteral corticosteroids). In close physical contact (household or at work) with an individual who has the diseases or conditions that cause immunodeficiency History or present of eczema or atopic dermatitis Allergy or sensitivity to any known components of vaccine or other medicines In close physical contact (household or at work) with an individual who has acute or chronic skin conditions such as dermatitis, exfoliative dermatitis Subjects requiring steroid therapy Subjects who are taking immunosuppressive therapy Subjects who are planning for blood donations Autoimmune disease such as lupus erythematosus Subjects who work in medical institution Household contacts with women who are pregnant or breast-feeding Female subjects who are pregnant or breast-feeding and have positive result by serum pregnancy test or urine pregnancy test, or do not using approved contraceptives such as sterilization, contraceptive ring injectable, combined oral contraceptive pills and barrier contraceptive, combined hormone-based therapy, contraceptive cream, contraceptive jelly, diaphragm or condoms Subjects household member < 1 year old or work with children < 1 year old Subjects with a known history of Cardiac disease or have three or more of the following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis, cerebral arteriosclerosis Receipt of immunoglobulin and steroid within 14 days of vaccination Receipt of investigational research agents within 120 days of vaccination HBsAg seropositive HCV antibody seropositive HIV seropositive Subjects having fever (oral temperature > 38℃) or severe nutrition disorder Blood donation within 12 weeks in advance screening visit Subject who are not suitable to participate in study according to investigator's judgement
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Myoung-don Oh, M.D.
Organizational Affiliation
Seoul National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of

12. IPD Sharing Statement

Citations:
PubMed Identifier
20600480
Citation
Jang HC, Kim CJ, Kim KH, Lee KH, Byun YH, Seong BL, Saletti G, Czerkinsky C, Park WB, Park SW, Kim HB, Kim NJ, Oh MD. A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers. Vaccine. 2010 Aug 16;28(36):5845-9. doi: 10.1016/j.vaccine.2010.06.063. Epub 2010 Jun 30.
Results Reference
derived

Learn more about this trial

Safety and Efficacy of CJ-50300 in Healthy Volunteers

We'll reach out to this number within 24 hrs